Your browser doesn't support javascript.
loading
Author Correction: Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population.
Westphalen, C B; Krebs, M G; Le Tourneau, C; Sokol, E S; Maund, S L; Wilson, T R; Jin, D X; Newberg, J Y; Fabrizio, D; Veronese, L; Thomas, M; de Braud, F.
Afiliação
  • Westphalen CB; Comprehensive Cancer Center Munich & Department of Medicine III, University Hospital, LMU Munich, Munich, Germany. cwestpha@med.lmu.de.
  • Krebs MG; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
  • Le Tourneau C; Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France, Saint-Cloud, France.
  • Sokol ES; INSERM U900 Research Unit, Saint-Cloud, France.
  • Maund SL; Paris-Saclay University, Paris, France.
  • Wilson TR; Foundation Medicine Inc., Cambridge, MA, USA.
  • Jin DX; Genentech Inc., South San Francisco, CA, USA.
  • Newberg JY; Genentech Inc., South San Francisco, CA, USA.
  • Fabrizio D; Foundation Medicine Inc., Cambridge, MA, USA.
  • Veronese L; Foundation Medicine Inc., Cambridge, MA, USA.
  • Thomas M; Foundation Medicine Inc., Cambridge, MA, USA.
  • de Braud F; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
NPJ Precis Oncol ; 5(1): 86, 2021 Sep 17.
Article em En | MEDLINE | ID: mdl-34535754
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article